Catholicism provided greater certainty than the Church of England, which was considered a wishy-washy institution by many in ...

For millions of Christians, the resurrection of Jesus is the cornerstone of their faith, a moment they believe rewrote ...

The General Director of Scripture Union Nigeria, Uwem Udoh, has urged Christians across the country to remain calm and ...

Tarsus Pharmaceuticals, Inc. is upgraded to Strong Buy with a 12-month price target of $100/share, driven by Xdemvy's rapid commercialization. Xdemvy remains the only approved treatment for Demodex ...

IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in a fireside chat at the Guggenheim 2 nd Annual ...

IRVINE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced financial results for the third quarter ended September 30, 2025. “Our third quarter ...

Saul Zabar, who ruled the iconic Upper West Side grocery store bearing his name for more than seven decades, died Tuesday. He was 97. The so-called lox-smith had been hospitalized with a brain bleed ...

During confession one Wednesday, I confessed to a persistent craving for alcohol. The first thing the priest said to me was, “How are your relationships?” My knee-jerk reaction was to say, “Fine.” But ...

Tarsus Pharmaceuticals has seen its stock drop 20% since late 2024, despite XDEMVY's strong early performance, which is powering impressive sales growth. The company remains focused on eye care ...

Saul of Tarsus is one of the most dramatic stories of repentance found in the Bible. Rabbi Gamaliel is unable to convince his friend Saul, the arch-enemy and persecutor of Christians, to mend his ways ...

The series is an educational non-sectarian collection of stories from the New Testament Bible, intended to encourage positive values and character traits in young people.

Tarsus Pharmaceuticals reports $78.3 million in Q1 2025 product sales, up 217% year-over-year, and outlines future clinical plans. Tarsus Pharmaceuticals, Inc. reported significant financial results ...